June 24, 2021 -- Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing of chimeric antigen receptor-natural killer (CAR-NK) cell therapies.
Under the collaboration, Bio-Techne will contribute its cell expansion technologies and both companies will contribute expertise to enable large-scale production of functional CAR-NK cells.
Catamaran now has license to Bio-Techne's rights related to the TcBuster transposon system for use in the manufacturing of allogenic cell therapies; it has integrated this system into its CAR-NK Tailwind platform.
The two firms' collaboration began in 2020, they said.
Financial details of the agreement were not disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
